Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more
Niagen Bioscience, Inc. (NAGE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.052x
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has a cash flow conversion efficiency ratio of 0.052x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.69 Million) by net assets ($70.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Niagen Bioscience, Inc. - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Niagen Bioscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Niagen Bioscience, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cohen Circle Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CCIR
|
-0.003x |
|
Lootom Telcovideo Network Wuxi Co Ltd
SHE:300555
|
-0.025x |
|
MGP Ingredients Inc
NASDAQ:MGPI
|
0.041x |
|
Time Publishing and Media Co Ltd Class A
SHG:600551
|
-0.006x |
|
Dnake Xiamen Intelligent Technology
SHE:300884
|
0.641x |
|
Chervon Holdings Limited
PINK:CHRHF
|
0.255x |
|
Lifestyle Communities Ltd
AU:LIC
|
0.028x |
|
BTQ Technologies Corp. Common Stock
NASDAQ:BTQ
|
-0.095x |
Annual Cash Flow Conversion Efficiency for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual cash flow conversion efficiency of Niagen Bioscience, Inc. from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $46.09 Million | $12.11 Million | 0.263x | +5.04% |
| 2023-12-31 | $28.46 Million | $7.12 Million | 0.250x | +147.50% |
| 2022-12-31 | $28.67 Million | $-15.10 Million | -0.527x | +30.86% |
| 2021-12-31 | $31.73 Million | $-24.16 Million | -0.762x | -18.00% |
| 2020-12-31 | $16.42 Million | $-10.60 Million | -0.645x | +35.44% |
| 2019-12-31 | $20.45 Million | $-20.44 Million | -1.000x | -29.95% |
| 2018-12-31 | $27.18 Million | $-20.91 Million | -0.769x | -322.42% |
| 2017-12-31 | $53.83 Million | $-9.80 Million | -0.182x | +38.14% |
| 2016-12-31 | $9.97 Million | $-2.94 Million | -0.294x | +26.44% |
| 2015-12-31 | $5.27 Million | $-2.11 Million | -0.400x | +37.98% |
| 2014-12-31 | $4.00 Million | $-2.58 Million | -0.645x | +6.39% |
| 2013-12-31 | $5.67 Million | $-3.91 Million | -0.689x | +72.79% |
| 2012-12-31 | $3.99 Million | $-10.12 Million | -2.534x | -58.35% |
| 2011-12-31 | $2.56 Million | $-4.10 Million | -1.600x | -196.80% |
| 2010-12-31 | $4.94 Million | $-2.66 Million | -0.539x | -42.56% |
| 2009-12-31 | $1.05 Million | $-396.17K | -0.378x | +65.57% |
| 2008-12-31 | $1.75 Million | $-1.92 Million | -1.098x | +99.49% |
| 2007-12-31 | $180.00 | $-38.48K | -213.794x | -- |